Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 192.72 Million INR | 76.6% |
| 2022 | 116.61 Million INR | 467.7% |
| 2021 | -31.71 Million INR | 76.73% |
| 2020 | -136.26 Million INR | -46.09% |
| 2019 | -93.27 Million INR | -427.87% |
| 2018 | -17.66 Million INR | -252.18% |
| 2017 | -5.01 Million INR | 49.62% |
| 2016 | -9.95 Million INR | 70.25% |
| 2015 | -33.47 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2011 | 302.17 Million INR | 2.14% |
| 2010 | 295.84 Million INR | 93.01% |
| 2009 | 153.27 Million INR | -10.85% |
| 2008 | 171.93 Million INR | -12.51% |
| 2007 | 196.52 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 56.91 Million INR | 61.08% |
| 2023 Q4 | 35.33 Million INR | -69.8% |
| 2023 FY | 205.93 Million INR | 76.6% |
| 2023 Q2 | 128.36 Million INR | 25.65% |
| 2023 Q1 | 102.16 Million INR | 257.54% |
| 2023 Q3 | 116.99 Million INR | -8.85% |
| 2022 Q3 | 74.61 Million INR | -1.27% |
| 2022 Q2 | 75.57 Million INR | 141.7% |
| 2022 Q1 | 31.26 Million INR | 158.64% |
| 2022 FY | 116.61 Million INR | 467.7% |
| 2022 Q4 | -64.84 Million INR | -186.91% |
| 2021 Q3 | 62.6 Million INR | 29.85% |
| 2021 Q2 | 48.21 Million INR | 227.69% |
| 2021 Q4 | -53.31 Million INR | -185.17% |
| 2021 FY | -31.71 Million INR | 76.73% |
| 2021 Q1 | -37.75 Million INR | -62.13% |
| 2020 Q3 | -41.34 Million INR | -3.43% |
| 2020 FY | -136.26 Million INR | -46.09% |
| 2020 Q4 | -23.28 Million INR | 43.67% |
| 2020 Q1 | -31.65 Million INR | -3.34% |
| 2020 Q2 | -39.97 Million INR | -26.25% |
| 2019 Q4 | -30.63 Million INR | -53.26% |
| 2019 FY | -93.27 Million INR | -427.87% |
| 2019 Q1 | -22.24 Million INR | -266.78% |
| 2019 Q2 | -20.54 Million INR | 7.68% |
| 2019 Q3 | -19.98 Million INR | 2.68% |
| 2018 Q2 | 8.84 Million INR | 185.7% |
| 2018 Q1 | -10.32 Million INR | -174.5% |
| 2018 FY | -17.66 Million INR | -252.18% |
| 2018 Q4 | -6.06 Million INR | 40.12% |
| 2018 Q3 | -10.13 Million INR | -214.5% |
| 2017 Q3 | 41.09 Million INR | 1904.08% |
| 2017 Q1 | -18.1 Million INR | -197.22% |
| 2017 Q4 | 13.85 Million INR | -66.28% |
| 2017 FY | -5.01 Million INR | 49.62% |
| 2017 Q2 | -2.27 Million INR | 87.42% |
| 2016 Q2 | -2.07 Million INR | 69.69% |
| 2016 FY | -9.95 Million INR | 70.25% |
| 2016 Q3 | -5.22 Million INR | -152.44% |
| 2016 Q1 | -6.83 Million INR | 75.08% |
| 2016 Q4 | 18.62 Million INR | 456.24% |
| 2015 Q1 | -10.77 Million INR | 0.0% |
| 2015 FY | -33.47 Million INR | 0.0% |
| 2015 Q2 | -8.59 Million INR | 20.24% |
| 2015 Q3 | -9.3 Million INR | -8.32% |
| 2015 Q4 | -27.42 Million INR | -194.66% |
| 2014 FY | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2013 Q2 | -112 Thousand INR | 0.0% |
| 2013 Q3 | - INR | 100.0% |
| 2012 Q3 | -8.58 Million INR | -147.28% |
| 2012 Q2 | 18.16 Million INR | 0.0% |
| 2011 Q3 | 73.55 Million INR | 9.25% |
| 2011 FY | 302.17 Million INR | 2.14% |
| 2011 Q4 | 98.02 Million INR | 33.28% |
| 2011 Q2 | 67.32 Million INR | 0.0% |
| 2010 FY | 295.84 Million INR | 93.01% |
| 2009 FY | 153.27 Million INR | -10.85% |
| 2008 FY | 171.93 Million INR | -12.51% |
| 2008 Q4 | 289.8 Million INR | 0.0% |
| 2007 FY | 196.52 Million INR | 0.0% |
| 2007 Q4 | 38.63 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 99.28% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.875% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 98.45% |
| Granules India Limited | 16.79 Billion INR | 98.853% |
| Indoco Remedies Limited | 6.04 Billion INR | 96.81% |
| Achyut Healthcare Limited | 4.86 Million INR | -3864.76% |
| Ajanta Pharma Limited | 21.06 Billion INR | 99.085% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.631% |
| Alpa Laboratories Limited | 188.89 Million INR | -2.029% |
| Brooks Laboratories Limited | 65.62 Million INR | -193.702% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 96.903% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 86.905% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 94.785% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.882% |
| Eris Lifesciences Limited | 10.42 Billion INR | 98.152% |
| FDC Limited | 8.33 Billion INR | 97.688% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.722% |
| Gufic Biosciences Limited | 4.16 Billion INR | 95.376% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 96.889% |
| Ipca Laboratories Limited | 29.8 Billion INR | 99.353% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 70.467% |
| Lasa Supergenerics Limited | 121.02 Million INR | -59.239% |
| Laurus Labs Limited | 24.62 Billion INR | 99.217% |
| Lupin Limited | 123.71 Billion INR | 99.844% |
| Mankind Pharma Limited | 44.52 Billion INR | 99.567% |
| Medicamen Biotech Limited | 495.49 Million INR | 61.104% |
| Medico Remedies Limited | 262.14 Million INR | 26.48% |
| Megasoft Limited | 342.07 Million INR | 43.659% |
| NATCO Pharma Limited | 25.73 Billion INR | 99.251% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.212% |
| RPG Life Sciences Limited | 2.48 Billion INR | 92.238% |
| Sigachi Industries Limited | 2 Billion INR | 90.375% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.925% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 95.326% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 79.549% |
| Unichem Laboratories Limited | 4.86 Billion INR | 96.038% |
| Wanbury Limited | 1.73 Billion INR | 88.864% |
| Windlas Biotech Limited | 1.33 Billion INR | 85.604% |
| ZIM Laboratories Limited | 1.26 Billion INR | 84.787% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.846% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 131.993% |
| Divi's Laboratories Limited | 32.44 Billion INR | 99.406% |
| Hester Biosciences Limited | 1.27 Billion INR | 84.868% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 96.666% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 87.618% |
| Bal Pharma Limited | 770.19 Million INR | 74.977% |
| Strides Pharma Science Limited | 14.38 Billion INR | 98.661% |
| Venus Remedies Limited | 2.18 Billion INR | 91.17% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 96.695% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 93.515% |
| Shilpa Medicare Limited | 3.54 Billion INR | 94.566% |
| Aarti Drugs Limited | 8.31 Billion INR | 97.683% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 95.793% |
| Suven Life Sciences Limited | -200.79 Million INR | 195.981% |
| Ind-Swift Limited | 2.17 Billion INR | 91.129% |
| Valiant Laboratories Limited | -60.66 Million INR | 417.696% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 99.151% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 77.621% |
| Themis Medicare Limited | 1.5 Billion INR | 87.185% |
| Hikal Limited | 3.14 Billion INR | 93.868% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.588% |
| Sequent Scientific Limited | 2.97 Billion INR | 93.53% |
| Novartis India Limited | 1.32 Billion INR | 85.475% |
| Wockhardt Limited | 16.24 Billion INR | 98.813% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 99.019% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -1221.886% |
| Neuland Laboratories Limited | 8.24 Billion INR | 97.663% |
| Morepen Laboratories Limited | 6.16 Billion INR | 96.872% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 68.939% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 72.609% |